DOCSLIB.ORG

Mortality from Respiratory Diseases

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Mortality from Respiratory Diseases II.3. HEALTH STATUS MORTALITY FROM RESPIRATORY DISEASES Mortality from respiratory diseases is the third Nearly 6 000 deaths were directly attributed to main cause of death in EU countries, accounting for influenza, with most of these deaths concentrated 8% of all deaths in 2015. More than 440 000 people among people aged over 65. But influenza also died from respiratory diseases in 2015, an increase of contributed to many more deaths among frail elderly 15% over the previous year. Most of these deaths (90%) people with chronic diseases. The European Monitoring were among people aged 65 and over. The main of Excess Mortality network estimated that up to causes of death from respiratory diseases are chronic 217 000 deaths were related to influenza among elderly obstructive pulmonary disease, pneumonia, asthma people across EU countries during the winter 2015 and influenza. (EuroMoMo, 2016). In 2015, the United Kingdom and Ireland had the The prevalence and mortality from respiratory highest age-standardised death rates from respiratory diseases are likely to increase in the coming years as diseases among EU countries (Figure 3.15). Finland, the population ages and presently unreported cases of Latvia, Estonia and Lithuania had the lowest rates, COPD begin to manifest, whether alone or in with rates only about half the EU average. co-morbidity with other chronic diseases. Death rates from respiratory diseases are on Many deaths from respiratory diseases could be average 85% higher among men than among women prevented by tackling some of the main risk factors, in all EU countries. This is partly due to higher notably smoking, and by increasing vaccination coverage smoking rates among men. Smoking is an important for influenza and pneumonia, particularly among elderly risk factor for chronic obstructive pulmonary disease people and other vulnerable groups. Better management and other respiratory diseases. of both asthma and COPD in primary care could also help Chronic obstructive pulmonary disease (COPD) (or reduce health complications. chronic lower respiratory diseases), which includes chronic bronchitis and emphysema, caused over 180 000 deaths in EU countries in 2015 and accounted Definition and comparability for over 40% of all respiratory disease mortality. Mortality rates are based on the number of Mortality from COPD varies widely across countries. deaths registered in a country in a year divided Hungary, Denmark and the United Kingdom have the by the population. The rates have been age- highest rate of mortality from COPD, with age- standardised to the revised European standard standardised rates at least two-thirds higher than the population adopted by Eurostat in 2012 to EU average (Figure 3.16). The main risk factor for COPD remove variations arising from differences in is tobacco smoking (both active and passive smoking), age structures across countries and over time. but other risk factors include occupational exposure to Deaths from respiratory diseases relate to dusts, fumes and chemicals, and air pollution more ICD-10 codes J00-J99, with pneumonia relating generally. A large number of people with COPD are only to J12-J18, chronic obstructive pulmonary diagnosed at a late stage, contributing to higher disease (or chronic lower respiratory diseases) mortality. People with COPD are also more susceptible relating to J40-J47 and asthma to J45-J46. The to influenza and pneumonia. international comparability of data on mortality Pneumonia was responsible for nearly from respiratory diseases can be affected by 140 000 deaths in EU countries in 2015, accounting for differences in medical training and coding over 30% of all respiratory disease mortality. As with practices for causes of death. Finland revised COPD, there are large variations in mortality rates some coding practices in 2005-06, leading across EU countries: Portugal, the Slovak Republic and especially to a decrease of recorded deaths the United Kingdom have the highest rates of caused by pneumonia. pneumonia mortality, whereas Finland, Greece and Austria have the lowest rates (Figure 3.17). The main risk factors for pneumonia are age, smoking and alcohol abuse, and having COPD or HIV infection References (Torres et al., 2013). Torres, A. et al. (2013), “Risk Factors for Community- More than 7 000 people died from asthma in EU acquired Pneumonia in Adults in Europe: A Literature countries in 2015. Mortality rates from asthma are Review”, Thorax, Vol. 68, pp. 1057-1065. highest in Estonia, Ireland and the United Kingdom, EuroMoMo (2016), “Excess mortality in Europe in the but remain much lower than for COPD and winter season 2014/15, in particular amongst the pneumonia. elderly”, Winter season summary 2015. 94 HEALTH AT A GLANCE: EUROPE 2018 © OECD/EUROPEAN UNION 2018 II.3. HEALTH STATUS 3.15. Respiratory diseases mortality, 2015 Total Women Men Age-standardised rates per 100 000 population 220 200 180 160 140 120 100 80 60 40 20 0 1. Three-year average (2013-15). Source: Eurostat Database. 1 2 http://dx.doi.org/10.1787/888933834547 3.16. COPD mortality, 2015 3.17. Pneumonia mortality, 2015 Latvia 14.4 Finland 2.8 France 16.8 Greece 9.5 Estonia 18.1 Austria 11.8 Bulgaria 21.2 Hungary 13.6 Slovenia 21.8 Cyprus ¹ 13.8 Poland 23.2 Croatia 15.2 Finland 23.7 Italy 16.0 Lithuania 24.7 Latvia 18.1 Malta ¹ 26.0 France 18.5 Cyprus ¹ 26.1 Luxembourg ¹ 19.4 Slovak Rep. 26.4 Bulgaria 19.7 Portugal 27.6 Lithuania 19.8 Greece 28.4 Estonia 20.4 Italy 30.6 Sweden 20.6 Sweden 31.0 Spain 20.6 Spain 34.5 Germany 23.2 Austria 35.7 Netherlands 24.7 EU28 36.3 EU28 28.1 Luxembourg ¹ 36.5 Czech Rep. 33.1 Romania 36.9 Denmark 36.5 Germany 39.3 Slovenia 37.7 Czech Rep. 40.8 Malta ¹ 37.7 Belgium 42.9 Belgium 37.7 Netherlands 47.6 Romania 38.5 Croatia 49.7 Ireland 42.1 Ireland 58.2 Poland 49.8 United Kingdom 60.9 United Kingdom 53.7 Denmark 69.2 Slovak Rep. 57.2 Portugal Hungary 72.5 57.7 Switzerland 27.5 Switzerland 19.2 Iceland ¹ 37.9 Serbia 21.7 Serbia 41.9 Iceland ¹ 28.1 Norway 51.4 Norway 33.7 Turkey 86.8 Turkey 41.5 0 20406080100 0 102030405060 Age-standardised rates per 100 000 population Age-standardised rates per 100 000 population 1. Three-year average (2013-15). 1. Three-year average (2013-15). Source: Eurostat Database. Source: Eurostat Database. 1 2 http://dx.doi.org/10.1787/888933834566 1 2 http://dx.doi.org/10.1787/888933834585 HEALTH AT A GLANCE: EUROPE 2018 © OECD/EUROPEAN UNION 2018 95 From: Health at a Glance: Europe 2018 State of Health in the EU Cycle Access the complete publication at: https://doi.org/10.1787/health_glance_eur-2018-en Please cite this chapter as: OECD/European Union (2018), “Mortality from respiratory diseases”, in Health at a Glance: Europe 2018: State of Health in the EU Cycle, OECD Publishing, Paris/European Union, Brussels. DOI: https://doi.org/10.1787/health_glance_eur-2018-12-en This work is published under the responsibility of the Secretary-General of the OECD. The opinions expressed and arguments employed herein do not necessarily reflect the official views of OECD member countries. This document and any map included herein are without prejudice to the status of or sovereignty over any territory, to the delimitation of international frontiers and boundaries and to the name of any territory, city or area. You can copy, download or print OECD content for your own use, and you can include excerpts from OECD publications, databases and multimedia products in your own documents, presentations, blogs, websites and teaching materials, provided that suitable acknowledgment of OECD as source and copyright owner is given. All requests for public or commercial use and translation rights should be submitted to [email protected]. Requests for permission to photocopy portions of this material for public or commercial use shall be addressed directly to the Copyright Clearance Center (CCC) at [email protected] or the Centre français d’exploitation du droit de copie (CFC) at [email protected]..
Load more

Recommended publications
  • 2014 05 08 BMJ Spontaneous Pneumothorax.Pdf
    BMJ 2014;348:g2928 doi: 10.1136/bmj.g2928 (Published 8 May 2014) Page 1 of 7 Clinical Review CLINICAL REVIEW Spontaneous pneumothorax Oliver Bintcliffe clinical research fellow, Nick Maskell consultant respiratory physician Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, Bristol BS10 5NB, UK Pneumothorax describes the presence of gas within the pleural and mortality than primary pneumothorax, in part resulting from space, between the lung and the chest wall. It remains a globally the reduction in cardiopulmonary reserve in patients with important health problem, with considerable associated pre-existing lung disease. morbidity and healthcare costs. Without prompt management Tension pneumothorax is a life threatening complication that pneumothorax can, occasionally, be fatal. Current research may requires immediate recognition and urgent treatment. Tension in the future lead to more patients receiving ambulatory pneumothorax is caused by the development of a valve-like leak outpatient management. This review explores the epidemiology in the visceral pleura, such that air escapes from the lung during and causes of pneumothorax and discusses diagnosis, evidence inspiration but cannot re-enter the lung during expiration. This based management strategies, and possible future developments. process leads to an increasing pressure of air within the pleural How common is pneumothorax? cavity and haemodynamic compromise because of impaired venous return and decreased cardiac output. Treatment is with Between 1991 and 1995 annual consultation rates for high flow oxygen and emergency needle decompression with pneumothorax in England were reported as 24/100 000 for men a cannula inserted in the second intercostal space in the and 9.8/100 000 for women, and admission rates were 16.7/100 midclavicular line.
    [Show full text]
  • Editorial Note on Pulmonary Fibrosis Sindhu Sri M*
    Editorial Note iMedPub Journals Archives of Medicine 2020 www.imedpub.com Vol.12 No. ISSN 1989-5216 4:e-105 DOI: 10.36648/1989-5216.12.4.e-105 Editorial Note on Pulmonary Fibrosis Sindhu Sri M* Department of Pharmaceutical Analytical Chemistry, Jawaharlal Nehru Technological University, Hyderabad, India *Corresponding author: Sindhu Sri M, Department of Pharmaceutical Analytical Chemistry, Jawaharlal Nehru Technological University, Hyderabad, India, E-mail: [email protected] Received date: July 20, 2020; Accepted date: July 26, 2020; Published date: July 31, 2020 Citation: Sindhu Sri M (2020) Editorial Note on Pulmonary Fibrosis. Arch Med Vol. 12 Iss.4: e105 Copyright: ©2020 Sindhu Sri M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Editorial Note • Lung fibrosis or pulmonary fibrosis. • Liver fibrosis. Pulmonary Fibrosis (PF) is a lung disease that happens when • Heart fibrosis. lung tissue gets harmed and scarred. Pulmonary meaning lung, • Mediastinal fibrosis. and fibrosis significance scar tissue. In the medical terminology • Retroperitoneal cavity fibrosis used to depict this scar tissue is fibrosis. The alveoli and the • Bone marrow fibrosis veins inside the lungs are responsible for conveying oxygen to • Skin fibrosis the body, including the brain, heart, and different organs. The • Scleroderma or systemic sclerosis PF group of lung diseases falls into a considerably large Hypoxia caused by pulmonary fibrosis can lead to gathering of ailments called the interstitial lung infections. At pulmonary hypertension, which, in turn, can lead to heart the point when an interstitial lung ailment incorporates scar failure of the right ventricle.
    [Show full text]
  • 8. Respiratory Pathology Respiratory System Structure and Function [Figs
    8. Respiratory pathology Respiratory system Structure and function [Figs. 8-1, 8-3] • Upper respiratory tract • structure • nasal cavity, sinuses, nasopharynx, • oral cavity, oropharynx • function • filter, warm, humidify air • Lower respiratory tract • structure • larynx, trachea • lungs (right and left) • function • air exchange • speech • Branching of airways into smaller ducts • bronchi → bronchioles → alveolar ducts → alveoli • Air exchange occurs in most distal spaces (alveoli) • diffusion barrier [Fig. 8-3] • alveolar pneumocyte, common basement membrane, endothelial cell • Respiratory defense mechanisms • mucus, mucocilliary escalator • alveolar macrophages • cough/ sneeze reflexes • Pulmonary circulation • dual blood supply Respiratory pathology Overview • Infections • Obstructive airway diseases • Restrictive airway diseases • Miscellaneous disorders • Neoplasms Infections of the upper respiratory tract • Common cold, sore throat, “Flu” • viral infection of upper respiratory tract with classic symptoms • rhinovirus, parainfluenza viruses • self limited, symptomatic relief • Strep throat • a bacterial infection caused by streptococcus A • diagnosed by identifying the bacteria, antibiotic therapy • Mononucleosis • a viral infection caused by EBV with enlarged nodes, sore throat • Diphtheria • a bacterial infection of the throat with formation of a membrane Respiratory pathology Infections, middle respiratory tract [Fig. 8-5] • Croup (3mo -3yo) • acute viral infection of the larynx in children younger than 3 yo • barking cough •
    [Show full text]
  • Community Acquired Pneumonia Sonia Akter*, Shamsuzzaman and Ferdush Jahan
    Akter et al. Int J Respir Pulm Med 2015, 2:1 International Journal of ISSN: 2378-3516 Respiratory and Pulmonary Medicine Review Article : Open Access Community Acquired Pneumonia Sonia Akter*, Shamsuzzaman and Ferdush Jahan Department of Microbiology, Dhaka Medical College, Bangladesh *Corresponding author: Sonia Akter, Department of Microbiology, Dhaka Medical College, Dhaka, Bangladesh, E-mail: [email protected] or residing in a long term care facility for > 14 days before the onset Abstract of symptoms [4]. Diagnosis depends on isolation of the infective Community-acquired pneumonia (CAP) is typically caused by organism from sputum and blood. Knowledge of predominant an infection but there are a number of other causes. The most microbial patterns in CAP constitutes the basis for initial decisions common type of infectious agents is bacteria such as Streptococcus about empirical antimicrobial treatment [5]. pneumonia. CAP is defined as an acute infection of the pulmonary parenchyma in a patient who has acquired the infection in the Microbial Pathogens community. CAP remains a common and potentially serious illness. It is associated with considerable morbidity, mortality and treatment Strep. pneumoniae accounted for over 80 percent of cases of cost, particularly in elderly patients. CAP causes problems like community-acquired pneumonia in the era before penicillin [6]. difficulty in breathing, fever, chest pains, and cough. Definitive Strep. pneumoniae is still the single most common defined pathogen clinical diagnosis should be based on X-ray finding and culture in nearly all studies of hospitalized adults with community-acquired of lung aspirates. The chest radiograph is considered the” gold pneumonia [7-9]. Other bacteria commonly encountered in cultures of standard” for the diagnosis of pneumonia but cannot differentiate bacterial from non bacterial pneumonia.
    [Show full text]
  • Swine Pneumonia
    L-5203 6/98 Swine Pneumonia Bruce Lawhorn* neumonia is an important disease of the lower respiratory tract that impairs animal health and lowers individual and herd Pperformance in swine. “Pneumonia” means inflamma- tion of the lungs. It may be minor, subsiding quickly, or develop into advanced pneumonia. The cause of the lung inflammation and the devel- opment of complications, such as secondary bacterial infection, generally determine how severe pneumonia becomes. Coughing and “thumping”(shallow, rapid breathing) are typical symptoms of pneumonia in swine. As the pneumonia becomes more severe, appe- tite and growth rate decrease, feed is utilized less effi- ciently, hogs may become chronic poor-doers, death may occur and treatment and control costs escalate. Possible causes of pneumonia are bacteria, viruses, parasites, extreme daily temperature fluctuations, chemicals (manure gas), dust and other respiratory tract irritants from the environment. Most of these are in- haled into the lungs. Infectious agents such as certain bacteria may reach the lungs through the blood stream. Parasites reach the lungs by larval migration through blood vessels, tissues and organs. defenses, predisposing them to secondary infection by Atrophic rhinitis and upper respiratory system dis- Pasteurella multocida and other bacteria. The second- ease in swine are discussed in the Extension fact sheet ary infection makes the lower respiratory disease worse L-2193, “Atrophic Rhinitis.” than with the M. hyopneumoniae infection alone. Bacterial Causes The combination of infections, first with M. hyopneumoniae, then with P. multocida, is considered Mycoplasma hyopneumoniae, the pneumonia agent the most frequent form of pneumonia, and is called present in virtually all swine herds, is transmitted from “common swine pneumonia” or enzootic pneumonia.
    [Show full text]
  • Chronic Respiratory Disease Strategic Plan, January 2017
    Chronic Respiratory Disease Strategic Plan As Required By S.B. 200, Sec. 2.31, 84th Legislature, Regular Session, 2015 Department of State Health Services January 2017 - This page is intentionally left blank - Table of Contents Executive Summary .......................................................................................................................3 Introduction ....................................................................................................................................5 Background ....................................................................................................................................5 Estimated Annual Direct and Indirect State Health Care Costs ...............................................8 Asthma .........................................................................................................................................8 Medicaid .................................................................................................................................. 8 Absenteeism Cost for Asthma ................................................................................................. 8 State of Texas Employees Previously Diagnosed with Asthma .............................................. 8 COPD ...........................................................................................................................................8 Medicaid .................................................................................................................................
    [Show full text]
  • Macrolide Therapy in Cryptogenic Organizing Pneumonia: a Case Report and Literature Review
    EXPERIMENTAL AND THERAPEUTIC MEDICINE 9: 829-834, 2015 Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review QUN‑LI DING, DAN LV, BI‑JIONG WANG, QIAO‑LI ZHANG, YI‑MING YU, SHI‑FANG SUN, ZHONG-BO CHEN, HONG-YING MA and ZAI-CHUN DENG Department of Respiratory Medicine, Affiliated Hospital, School of Medicine, Ningbo University, Ningbo, Zhejiang 315020, P.R. China Received May 9, 2014; Accepted December 15, 2014 DOI: 10.3892/etm.2015.2183 Abstract. Cryptogenic organizing pneumonia (COP) is a pneumonia (1,2). Secondary OP is associated with a number of pulmonary disorder associated with nonspecific clinical entities, including drugs, infections, malignancies, connective presentations. The macrolide class of antimicrobial agents is tissue diseases, organ transplantation, radiotherapy and the widely used to treat infectious and inflammatory respiratory inhalation of harmful gases. COP mainly involves the alveoli, diseases in humans. The present study reports a case of COP alveolar ducts and small airways; however, the lung intersti- that was effectively treated with azithromycin in combination tium may also be involved. It is considered as an inflammatory with glucocorticoid. A literature review of similar cases is disease and diagnosed based on the clinical, radiographic and also presented. It was found that all COP patients in the litera- pathological findings following the exclusion of diseases asso- ture received macrolide treatment, including six cases with ciated with secondary OP (3). Glucocorticoids are effective in unknown clinical outcomes. For the remaining 29 patients, the treatment of COP. However, glucocorticoids usually take a 20 patients initially received the macrolide as a single therapy longer time to take effect, and this results in severe side-effects.
    [Show full text]
  • Upper and Lower Respiratory Disease, Edited by J
    UPPER AND LOWER R ESP1RAT0 RY DISEASE Edited by Jonathan Corren Allergy Research Foundation, Inc. Los Angeles, California, U.S.A. Alkis Togias Johns Hopkins Asthma and Allergy Center Baltimore, Maryland, U.S.A. Jean Bousquet Hdpital Arnaud de Villeneuve Montpellier, France MARCEL MARCELDEKKER, INC. NEWYORK RASEL DEKKER Although great care has been taken to provide accurate and current information, neither the author(s) nor the publisher, nor anyone else associated with this publica- tion, shall be liable for any loss, damage, or liability directly or indirectly caused or alleged to be caused by this book. The material contained herein is not intended to provide specific advice or recommendations for any specific situation. Trademark notice: Product or corporate names may be trademarks or registered trade- marks and are used only for identification and explanation without intent to infringe. Library of Congress Cataloging-in-Publication Data A catalog record for this book is available from the Library of Congress. ISBN: 0-8247-0723-0 This book is printed on acid-free paper. Headquarters Marcel Dekker, Inc., 270 Madison Avenue, New York, NY 10016, U.S.A. tel: 212-696-9000; fax: 212-685-4540 Distribution and Customer Service Marcel Dekker, Inc., Cimarron Road, Monticello, New York 12701, U.S.A. tel: 800-228-1160; fax: 845-796-1772 Eastern Hemisphere Distribution Marcel Dekker AG, Hutgasse 4, Postfach 812, CH-4001 Basel, Switzerland tel: 41-61-260-6300; fax: 41-61-260-6333 World Wide Web http://www.dekker.com The publisher offers discounts on this book when ordered in bulk quantities.
    [Show full text]
  • Idiopathic Pulmonary Fibrosis
    IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis UPDATE 2019 and Management An ATS Pocket Publication ATS Pocket Guide _v11_051319 copy.indd 1 5/13/19 10:51 AM GUIDELINES FOR THE DIAGNOSIS AND MANAGEMENT OF IDIOPATHIC PULMONARY FIBROSIS: UPDATE 2019 AN AMERICAN THORACIC SOCIETY POCKET PUBLICATION This pocket guide is a condensed version of the 2011, 2015 and 2018 American Thoracic Society (ATS), European Respiratory Society (ERS), Japanese Respiratory Society (JRS), and Latin American Thoracic Association (ALAT) Evidence-Based Guidelines for Diagnosis and Management of Idiopathic Pulmonary Fibrosis (IPF). This pocket guide was complied by Ganesh Raghu, MD and Bridget Collins, MD, University of Washington, Seattle from excerpts taken from the published official documents of the ATS. Readers are encouraged to consult the full versions as well as the online supplements, which are available at http://ajrccm.atsjournals.org/content/183/6/788.long. All information in this pocket guide is derived from the 2011, 2015 and 2018 IPF guidelines unless otherwise noted. Some tables and figures are reprinted with the permission from the journals referenced. Produced in Collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. 2 Guidelines for the Diagnosis and Management of Idiopathic Pulmonary Fibrosis ATS Pocket Guide _v11_051319 copy.indd 2 5/13/19 10:51 AM CONTENTS List of Figures and Tables ..................................................................................................................4 List of Abbreviations and Acronyms
    [Show full text]
  • Respiratory Symptoms in Children and Exposure to Pesticides
    Copyright #ERS Journals Ltd 2003 Eur Respir J 2003; 22: 507–512 European Respiratory Journal DOI: 10.1183/09031936.03.00107403a ISSN 0903-1936 Printed in UK – all rights reserved Respiratory symptoms in children and exposure to pesticides P.R. Salameh*, I. Baldi#, P. Brochard#, C. Raherison#, B. Abi Saleh*, R. Salamon# Respiratory symptoms in children and exposure to pesticides. P.R. Salameh, I. Baldi, *Faculty of Public Health, Lebanese University, P. Brochard, C. Raherison, B. Abi Saleh, R. Salamon. #ERS Journals Ltd 2003. Fanar, Lebanon. #Faculty of Public Health, ABSTRACT: In Lebanon, childhood asthma is an important disease and pesticides are Institute of Public Health, Epidemiology and commonly used. The objective of this study was to evaluate whether exposure to Development, Victor Segalen Bordeaux 2 University, Bordeaux, France. pesticides has chronic effects on the respiratory health of Lebanese children. A cross-sectional study was performed on children from a randomly selected sample Correspondence: P. Salameh, Jdeidet El of Lebanese public schools. Exposure to pesticides was evaluated by a standardised Meten, Chalet Suisse Str., Ramza Azzam questionnaire and a residential exposure score, and respiratory symptoms were assessed Bldg, 5th floor, Beirut, Lebanon. by using the American Thoracic Society standardised questionnaire. Fax: 961 9934164 A chronic respiratory disease was reported in 407 (12.4%) out of 3,291 children. The E-mail: [email protected] baseline difference in mean age was small but statistically significant. Any exposure to pesticides, including residential, para-occupational and domestic, was associated with Keywords: Asthma, domestic, exposure, para- respiratory disease and chronic respiratory symptoms (chronic phlegm, chronic occupational, pesticides, respiratory wheezing, ever wheezing), except for chronic cough.
    [Show full text]
  • Aspiration Pneumonia in Dogs: Pathophysiology, Prevention, and Diagnosis
    3 CE Credits Aspiration Pneumonia in Dogs: Pathophysiology, Prevention, and Diagnosis Heidi M. Schulze, DVM, DACVECC Alta Vista Animal Hospital Ottawa, Ontario, Canada Louisa J. Rahilly, DVM, DACVECC Cape Cod Veterinary Specialists Buzzards Bay, Massachusetts Abstract: Aspiration pneumonia and aspiration pneumonitis are associated with significant morbidity in veterinary and human medicine. A variety of medical conditions and medications can predispose patients to aspiration, and every precaution should be taken to prevent aspiration from occurring. For dogs that aspirate oral or gastric contents and subsequently develop pneumonia, monitoring and supportive care are imperative. This article discusses the pathophysiology, prevention, and diagnosis of aspiration pneumonia. For more information, please see the companion article, “Aspiration result.4 The second phase of aspiration pneumonia begins 4 to 6 Pneumonia in Dogs: Treatment, Monitoring, and Prognosis.” hours after aspiration, lasts for 12 to 48 hours, and is characterized by infiltration of neutrophils into the alveoli and pulmonary intersti- ulmonary aspiration is the inhalation of fluid and/or particu- tium.1,3 This inflammatory phase is characterized by ongoing lates into the airways. In clinical medicine, aspirated material vascular leakage of proteins with continued development of high- comes from the contents of the gastric and/or oral cavities. protein pulmonary edema, neutrophil sequestration and activation, P 3,4 Aspiration pneumonitis is the result of inhalation of these contents and release of further proinflammatory cytokines. These first into the respiratory tract with subsequent inflammation of the two stages constitute aspiration pneumonitis. The third phase, airways and pulmonary parenchyma.1–3 Aspiration pneumonia is which constitutes the dif- a bacterial infection of the pulmonary parenchyma that develops ference between aspiration secondary to aspiration.
    [Show full text]
  • Respiratory Disease Screening in School-Aged Children Using Portable Spirometry
    0021-7557/11/87-02/123 Jornal de Pediatria Copyright © 2011 by Sociedade Brasileira de Pediatria ARTIGO ORIGINAL Respiratory disease screening in school-aged children using portable spirometry Rastreio de patologia respiratória em crianças em idade escolar com o uso de espirometria portátil Carolina Constant1, Isabel Sampaio1, Filipa Negreiro2, Pedro Aguiar3, Ana Margarida Silva4, Marisa Salgueiro4, Teresa Bandeira5 Resumo Abstract Objetivos: Avaliar a prevalência de doença respiratória em crianças Objectives: To assess the prevalence of respiratory disease in school- em idade escolar e determinar o valor da espirometria de campo. aged children and to determine the value of field spirometry. Métodos: Avaliaram-se 313 alunos do primeiro e quarto ano de Methods: Data on 313 1st and 4th graders from four public schools quatro escolas de Lisboa. Aplicou-se questionário respiratório auto- in Lisbon were analyzed. A respiratory self-answered questionnaire and preenchido, e efetuou-se espirometria. Realizou-se análise descritiva e standard spirometry were performed. Descriptive and bivariate analysis bivariada seguida de análise de regressão logística múltipla. was followed by multiple logistic regression. Resultados: Trinta e cinco por cento das crianças tiveram pelo Results: Thirty-five percent of the children presented at least one menos um episódio de sibilância (18% ≥ 2 episódios), e 4% tiveram episode of wheezing (18% ≥ 2 episodes), and 4% had asthma. Wheezing diagnóstico de asma. Sibilância foi mais frequente com história familiar was more frequent with family history of atopy (adjusted OR = 2.7; de atopia (OR ajustado = 2,7, IC95% 1,4-5,1), tabagismo na gravidez, 95%CI 1.4-5.1), maternal smoking during pregnancy, lower respiratory infecção respiratória baixa (IRB) (OR ajustado = 2,8; IC95% 1,2-6,2), tract infection (LRTI) (adjusted OR = 2.8; 95%CI 1.2-6.2), bronchiolitis bronquiolite (OR ajustado = 3,3; IC95% 1,3-8,2) e alergia a aeroalér- (adjusted OR = 3.3; 95%CI 1.3-8.2), and allergy to aeroallergens genos (OR ajustado = 3,2; IC95% 1,4-7,2).
    [Show full text]